Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirum Pharmaceuticals reports robust Q4 performance and growth strategies

Mirum Pharmaceuticals showcased strong financial performance and strategic growth initiatives in their Q4 2022 earnings call, driven by significant sales growth and positive study outcomes.
While the company faces challenges in maintaining market position and regulatory milestones, opportunities lie in upcoming milestones, product expansion, and market penetration strategies.
Overall, Mirum Pharmaceuticals' performance reflects a promising outlook for continued growth and innovation in the pharmaceutical sector, supported by a solid financial foundation and product pipeline.

Mirum Pharmaceuticals reports strong Q1 revenue and strategic growth plans

Mirum Pharmaceuticals' Q1 2023 earnings call showcased strong revenue performance, strategic initiatives, and promising pipeline milestones. The company's focus on LIVMARLI and expansion efforts position it well for future growth, despite facing regulatory and commercial challenges.

Mirum Pharmaceuticals reports robust Q2 performance and eyes strategic growth

Mirum Pharmaceuticals showcased strong financial performance, strategic progress, and a focus on innovation during the Q2 2023 earnings call.
The company's emphasis on pediatric hepatology, upcoming acquisitions, and commitment to bringing important medicines to patients globally position it for future success.
While facing challenges such as regulatory strategies and integration post-acquisition, Mirum has opportunities to drive growth through product expansion and market leadership.

Mirum Pharmaceuticals reports strong Q3 revenue and strategic acquisitions

Mirum Pharmaceuticals demonstrated solid performance in Q3 2023 with strong revenue and strategic acquisitions.
While facing challenges such as net losses and high operating expenses, the company maintains a strong financial position.
Opportunities lie in upcoming milestones, product commercialization, and financial optimization under new leadership.
Overall, Mirum Pharmaceuticals shows promise for growth and innovation in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q4 earnings and growth opportunities

Mirum Pharmaceuticals delivered strong financial results in Q4 2023, with significant revenue growth and net product sales.
Despite operating expenses and a net loss, the company remains well-funded and poised for growth in 2024.
Key milestones and progress in pipeline development highlight Mirum's commitment to innovation and market expansion.
Balancing financial performance with pipeline advancement and regulatory milestones will be crucial for Mirum's sustained success in the pharmaceutical industry.

Mirum Pharmaceuticals reports robust Q1 sales growth and pipeline advancements

Mirum Pharmaceuticals demonstrated strong sales growth and financial stability in Q1 2024, driven by the success of LIVMARLI and advancements in product pipeline.
While facing challenges in managing expenses and navigating a competitive market, Mirum's focus on rare liver disease treatments presents significant opportunities for growth.
The company's commitment to innovation, gratitude for stakeholders, and strategic plans for NDA submissions underscore a promising outlook for future success.
Investors should monitor Mirum's progress in commercializing key products and expanding its market reach to capitalize on the growth potential in rare disease treatments.

Mirum Pharmaceuticals excels in Q2, eyes global expansion and innovation

Mirum Pharmaceuticals demonstrated impressive growth and achieved key milestones in Q2 2024, positioning the company for future success.
While facing challenges such as net losses and market competition, Mirum's strengths in product innovation and market expansion offer opportunities for sustained growth.
By focusing on cost management, regulatory compliance, and strategic partnerships, Mirum can navigate challenges and capitalize on opportunities to drive long-term value for stakeholders.

Mirum Pharmaceuticals excels in Q3, raises revenue guidance and expands pipeline

Mirum Pharmaceuticals delivered exceptional results in Q3 2024, showcasing strong financial performance, robust commercial programs, and promising pipeline advancements. With increased revenue guidance, breakthrough designations, and positive cash flow, the company is well-positioned for continued success. Challenges lie in maintaining growth momentum amidst competition and regulatory complexities, but opportunities for expansion and innovation abound.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CyberOptics

These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.

CyberOptics, Mirum Pharmaceuticals See Activist Action

Following the public offering, Mirum is in an excellent financial position to accelerate both the Livmarli launch and the clinical development pipeline. The biggest value driver is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 million in the U.S. alone.

Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the closing of its previously announced underwritten public offering of 4,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 521,739 shares, at a price to

Mirum Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Common Stock

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share. The gross proceeds to Mirum from the offering, before deducting underwriting d

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $80.0 million of shares of its common stock. In connection with the proposed offering, Mirum expects to grant the underw

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Clements - CFO Chris Peetz - President and CEO Peter Radovich - COO Pam Vig - Head, R&D Conference Call Participants Jessica Fye - JPMorgan Lili Nsongo - SVB Ed Arce - H.C. Wainright Ryan Deschner - Raymond James Operator Good afternoon.

Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2022 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report second quarter financial results on Thursday, August 4, 2022. That same day, Mirum will host a conference call to discuss the company's progress and priorities for 2022. Conference call details: Thursday, August 4, 2022 4:30 p.m. ET / 1:30 p.m. PT Dial-in: U.S./Toll-Free: 1 (888) 510-2553 International: 1 (646) 960-0473 Passcode: 9354200 You may also access the call via webcast b

Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with ALGS at ESPGHAN Annual Meeting

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)

Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

Mirum's maralixibat was approved in September. The company looks like it is executing very well.

Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM ) Q1 2022 Results Conference Call May 5, 2022 8:30 AM ET Company Participants Chris Peetz - President, CEO Ian Clements - CFO Peter Radovich - COO Pam Vig - Head, R&D Conference Call Participants Ed Arce - H.C. Wainwright Brian Skorney - Baird Nick Lenard - JPMorgan Josh Schimmer - Evercore Rick Bienkowski - SVB Ryan Deschner - Raymond James Yasmeen Rahimi - Piper Sandler Operator Hello, and welcome to the Mirum Pharmaceuticals first quarter business update.

Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q1 2022 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter financial results on Thursday, May 5, 2022. That same day, Mirum will host a conference call to discuss the company's progress and priorities for 2022. Conference call details: Thursday, May 5, 2022 8:30 a.m. ET/5:30 a.m. PT Dial-in: U.S./Toll-Free: 844-200-6205 International: 646-904-5544 Passcode: 717854 You may also access the call via webcast by visiting the Eve

Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q4 2021 Results - Earnings Call Transcript

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End Business Results for 2021 and Host Conference Call on March 9, 2022

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

Since Mirum Pharmaceuticals' Livmarli was approved for the treatment of cholestatic pruritus in patients with Alagille syndrome, its stock has fallen some 25%. Although the only approved therapy for ALGS, maralixibat faces competition via Albireo's Bylvay, which has a first-mover advantage in at least one other bile acid indication.

News for Mirum Pharmaceuticals Inc Stock (MIRM)